Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial

BACKGROUND: Rituximab and tacrolimus are therapies reserved for patients with frequently relapsing or steroid-dependent nephrotic syndrome who have failed conventional steroid-sparing agents. Given their toxicities, demonstrating non-inferiority of rituximab to tacrolimus may enable choice between t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Georgie, Sinha, Aditi, Ahmed, Aijaz, Grewal, Neetu, Khandelwal, Priyanka, Hari, Pankaj, Bagga, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919684/
https://www.ncbi.nlm.nih.gov/pubmed/35286456
http://dx.doi.org/10.1007/s00467-022-05475-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919684/
https://www.ncbi.nlm.nih.gov/pubmed/35286456
http://dx.doi.org/10.1007/s00467-022-05475-8

Ejemplares similares